NCT04758949View on ClinicalTrials.gov

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 25, 2021

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

FL-101

200 mg administered intravenously every 2 weeks prior to surgery.

DRUG

Nivolumab

240 mg administered intravenously every 2 weeks prior to surgery.

DRUG

Placebo

200 mg administered intravenously every 2 weeks prior to surgery.

Sponsors

Lead Sponsor

Flame Biosciences
All Listed Sponsors
lead

Flame Biosciences

INDUSTRY